National Bank of Canada’s Royalty Pharma RPRX Stock Holding History

National Bank of Canada’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$369K	Buy	7,687 +2,091	+37%	+$91.6K	﹤0.01%	1469
2025 Q4	$216K	Buy	5,596 +2,908	+108%	+$111K	﹤0.01%	1578
2025 Q3	$94.8K	Buy	2,688 +216	+9%	+$7.82K	﹤0.01%	1773
2025 Q2	$89.1K	Buy	2,472 +426	+21%	+$14.1K	﹤0.01%	1813
2025 Q1	$63.7K	Sell	2,046 -28	-1%	-$888	﹤0.01%	1811
2024 Q4	$53K	Buy	2,074 +371	+22%	+$9.84K	﹤0.01%	1934
2024 Q3	$48.2K	Buy	1,703 +78	+5%	+$2.16K	﹤0.01%	1718
2024 Q2	$42.6K	Buy	1,625 +87	+6%	+$2.41K	﹤0.01%	1743
2024 Q1	$43.2K	Sell	1,538 -33,334	-96%	-$983K	﹤0.01%	1809
2023 Q4	$986K	Sell	34,872 -79,441	-69%	-$2.18M	﹤0.01%	1157
2023 Q3	$3.08M	Buy	114,313 +15,802	+16%	+$469K	﹤0.01%	941
2023 Q2	$3.03M	Sell	98,511 -7,900	-7%	-$268K	0.01%	867
2023 Q1	$3.82M	Buy	106,411 +68,765	+183%	+$2.55M	0.01%	669
2022 Q4	$1.49M	Sell	37,646 -59,433	-61%	-$2.48M	﹤0.01%	959
2022 Q3	$3.9M	Buy	97,079 +72,144	+289%	+$3.08M	0.02%	597
2022 Q2	$1.06M	Sell	24,935 -10,249	-29%	-$420K	﹤0.01%	999
2022 Q1	$1.55M	Buy	35,184 +12,589	+56%	+$494K	﹤0.01%	955
2021 Q4	$885K	Buy	+22,595	New	+$878K	﹤0.01%	1098

Other funds holding RPRX

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

National Bank of Canada's RPRX Position: Q1 2026 in Review

National Bank of Canada increased its Royalty Pharma (RPRX) stake by 37% in Q1 2026, buying an estimated $91.6K and bringing the position to 7,687 shares worth $369K. The position accounts for ﹤0.01% of the portfolio, ranked #1469.

National Bank of Canada first reported a position in RPRX in Q4 2021 and has held it in 18 quarters since. The position peaked at $3.9M in Q3 2022. 588 funds tracked by Wall St. Rank hold RPRX as of Q1 2026.

National Bank of Canada held 7,687 shares of Royalty Pharma worth $369K as of Q1 2026.
National Bank of Canada bought 2,091 Royalty Pharma shares in Q1 2026, an estimated $91.6K.
Royalty Pharma made up ﹤0.01% of National Bank of Canada's portfolio in Q1 2026, its #1469 holding.
National Bank of Canada first reported a position in Royalty Pharma in Q4 2021 and has held it in 18 quarters since.
National Bank of Canada's Royalty Pharma position peaked at $3.9M in Q3 2022.
588 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2026.

Based on National Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.